-
1 Comment
Wuhan Easy Diagnosis Biomedicine Co.,Ltd is currently in a long term uptrend where the price is trading 15.7% above its 200 day moving average.
From a valuation standpoint, the stock is 30.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 6.7.
Wuhan Easy Diagnosis Biomedicine Co.,Ltd's total revenue rose by 637.9% to $280M since the same quarter in the previous year.
Its net income has increased by 3353.4% to $156M since the same quarter in the previous year.
Finally, its free cash flow grew by 279.5% to $30M since the same quarter in the previous year.
Based on the above factors, Wuhan Easy Diagnosis Biomedicine Co.,Ltd gets an overall score of 5/5.
| ISIN | CNE1000033Q7 |
|---|---|
| Sector | Healthcare |
| CurrencyCode | CNY |
| Exchange | SHE |
| Industry | Medical Devices |
| Market Cap | 5B |
|---|---|
| Target Price | None |
| PE Ratio | 132.0 |
| Dividend Yield | 5.6% |
| Beta | 0.6 |
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. engages in the research and development, production, and sale of vitro diagnostic reagents and diagnostic instruments in China. The company offers external diagnostic testing, third-party medical testing, certification consulting services, and medical information platform construction services. It also provides information software and supporting hardware products. Wuhan Easy Diagnosis Biomedicine Co.,Ltd. was founded in 2008 and is based in Wuhan, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 002932.SHE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
